COVID-19 vaccine comparison Biontech/Pfizer vs Moderna 2020

Published by
Matej Mikulic,
Jul 27, 2022
In November 2020, COVID-19 vaccines from the Biontech/Pfizer cooperation and from Moderna showed very good results in phase III of clinical trials. Both sites reported nearly the exact same efficacy of around 95 percent. Pfizer and BioNTech will probably be able to produce larger amounts until year-end 2020 and also during 2021.

Comparison of the COVID-19 vaccines developed by BioNTech/Pfizer and Moderna as of November 2020

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

November 2020

Region

Worldwide

Survey time period

as of November 2020

Supplementary notes

* BioNTech/Pfizer: 1 severe case out of 8; Moderna: 0 severe case out of 5.
** BioNTech/Pfizer: 9 severe cases out of 162; Moderna: 11 severe cases out of 95.
*** Maximum estimate for Moderna.

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Coronavirus: the pharma and medtech response "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Further related statistics

19

Further Content: You might find this interesting as well

Statistics

Topics

Small and medium-sized biotech companiesGlobal pharmaceutical industryBiotech drugsTop pharmaceutical drugsBiotechnology in Europe
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.
Menu